NIPH Clinical Trials Search

Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patient with type2 diabetes and chronic kidney disease.

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	type2 diabetes meliitus
Date of first enrollment	2016/05/02
Target sample size	30
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Distribution to a group as administration of sitagliptin 25mg for three months, followed by administration of teneligliptin 20mg for three months Distribution to a group as administration of teneligliptin 20mg for three months, followed by administration of sitagliptin 25mg for three months

Outcome(s)

Primary Outcome	Changes in blood glucose and HbA1c
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	100years-old
Gender	Male and Female
Include criteria
Exclude criteria	Patients of both drugs is contraindicated Pregnancy, patients in nursing Patients suffering from a severe disease requiring hospitalization Patients with anemia (Hb <10g / dl) Patients undergoing steroid therapy Patients attending physician was found to be inappropriate for any reason